United States Ex Rel. Bogart v. King Pharmaceuticals

414 F. Supp. 2d 540, 2006 U.S. Dist. LEXIS 4632, 2006 WL 293582
District Court, E.D. Pennsylvania·Decided February 7, 2006·No. Civ.A.03-1538·Published·Cited by 2 cases

Opinion

MEMORANDUM & ORDER

KATZ, Senior District Judge.

AND NOW, this 7th day of February, 2006, upon consideration of the State Government Plaintiffs’ and District of Columbia’s (collectively, “the States”) Consolidated Opposition to and Motion for Summary Judgment Dismissing the Relator’s Claims for a Share from State Settlements, it is hereby ORDERED that said Motion is GRANTED based on Relator’s failure to comply with the procedural requirements of the States’ qui tarn statutes.

Statement of Undisputed Facts

On March 11, 2003, defendant King Pharmaceuticals (“King”) issued a press release informing the public that it had received a letter from the SEC stating that King was under investigation. King also announced that the letter was accompanied by a subpoena for documents. King stated that the subpoenaed documents included, inter alia, King’s “ ‘best price’ lists,” and documents relating to the pricing of King’s pharmaceutical products to any governmental Medicaid agency during 1999.

The action was originally filed in this court on March 12, 2003. Under the March 12, 2003 Complaint (the “Original Complaint”), the District of Columbia and each of the State Government Plaintiffs except New Mexico and Virginia were named plaintiffs in that action. Count III thereof was fried by the Relator on behalf of the State of Illinois and asserted claims under 740 ILCS 175 et seq. (Illinois Whistleblower Reward and Protection Act). Count V thereof was filed by the Relator on behalf of the State of Florida and asserted claims under Fla. Stat. § 68.082 et seq. (Florida False Claims Act). Count VI thereof was fried by the Relator on behalf of the State of Texas and asserted claims under V.T.C.A. Hum. Res.Code § 36.001 et seq. (Texas False Claims Act). Count VII thereof was filed by the Relator on behalf of the Commonwealth of Massachusetts and asserted claims under M.D.L.C. 12, §§ 5A et seq. (Massachusetts False Claims Act). Count VIII thereof was filed by the Relator on behalf of the State of Tennessee Medicaid False Claims Act. Count IX thereof was filed by the Relator on behalf of the State of Delaware and asserted claims under 6 Del. C. § 1.20(a) et seq. (Delaware False Claims and Reporting Act). Count XI thereof was filed by the Relator on behalf of the State of Louisiana and asserted claims under the Louisiana Medical Assistance Programs Integrity Law (La. R.S. 46:437.1 et seq.). Count XII thereof was filed by the Relator on behalf the State of Hawaii and asserted claims under Haw. Rev. Stat § 661-21 et seq. (Hawaii False Claims Act). Count XIII thereof was filed by the Relator on behalf of the District of Columbia and asserted claims under D.C.Code § 2-308.13 et seq. (District of Columbia Procurement Reform Amendment Act).

The Relator made no disclosures to any of the State Government Plaintiffs relating to any of the claims in the Original Com *542 plaint prior to its filing. Relator’s Findings of Facts and Conclusions of Law on the Issues of Public Disclosure, Original Source, and Relator’s Entitlement to Recovery (“Relator’s Findings”) at ¶ 188.

The Relator did not provide copies of or otherwise serve the Original Complaint or otherwise give notice to any of the State Government Plaintiffs of any of the allegations in the Original Complaint until on or about June 17, 2004, over 15 months later. Relator’s Findings at ¶ 188.

On March 14, 2003, a complaint was filed in the United States District Court for the Eastern District of Tennessee in a case entitled Pechter v. King Pharmaceuticals, et al, C.A. 2:02-cv-00081. The Complaint in that case was and is a matter of public record.

On March 31, 2003, While Bogart’s qui tarn complaint was under seal, King filed an SEC Form 8-K, disclosing to the public that its calculations relating to Medicaid had not followed prescribed methodologies. See Declaration of William L. Phillips III in Support of Defendants’ Memorandum of Law in Opposition to Relator’s Motion for a Preliminary Injunction at ¶ 6 (“Phillips Declaration”). King reported this in a Press Release to the public. See Press Release, King Pharmaceuticals, Inc., 15-Day Extension for Form 10-K Filed by King Pharmaceuticals (March 31, 2003).

The First Amended Complaint was filed on or about July 2, 2003. Each of the State Government Plaintiffs and the District of Columbia named in the Original Complaint was also a named plaintiff in the First Amended Complaint, but the First Amended Complaint also asserted an additional count, labeled Count XIII, under Va.Code § 8.01 — 216.01 et seq. (Virginia Fraud Against Taxpayer Act). See First Amended Complaint.

The Relator made no disclosures to any of the State Government Plaintiffs relating to any of the claims in the First Amended Complaint prior to its filing. Relator’s Findings at ¶ 188.

The Relator did not provide copies of or otherwise serve the First Amended Complaint or otherwise give notice to any of the State Government Plaintiffs of any of the allegations in the First Amended Complaint until on or about June 17, 2004, over 11 months later. Relator’s Findings at ¶ 188.

The Second Amended Complaint was filed on or about June 17, 2004. Each of the State Government Plaintiffs named in the First Amended Complaint and the District of Columbia were also named plaintiffs in the Second Amended Complaint and the Second Amended Complaint also asserted claims under each of those states’ false claims acts. The Second Amended Complaint also added an additional count, again labeled Count XIII, asserting claims for the first time under the New Mexico Medicaid False Claims Act. See Second Amended Complaint.

The Relator made no disclosures to any of the State Government Plaintiffs relating to any of the claims in the Second Amended Complaint prior to its filing. Relator’s Findings at ¶¶ 188,189.

The Relator’s initial disclosure and notice to any of the State Government Plaintiffs was made under cover of a letter dated June 17, 2004 from Joel Androphy enclosing copies of the Second Amended Complaint, Initial Disclosure Statement and fifteen supplements. This letter was sent only to the office of each State Government Plaintiffs Attorney General. Relator’s Findings at ¶¶ 188,189.

The Third Amended Complaint was filed on or about September 22, 2004. Each of the State Government Plaintiffs named in the Second Amended Complaint and the District of Columbia were also named plaintiffs in the Third Amended Complaint *543 and the Third Amended Complaint also asserted claims under each of those states’ false claims acts. See Third Amended Complaint.

Free access — add to your briefcase to read the full text and ask questions with AI

United States Ex Rel. Bogart v. King Pharmaceuticals, 414 F. Supp. 2d 540, 2006 U.S. Dist. LEXIS 4632, 2006 WL 293582 (E.D. Pa. 2006).

414 F. Supp. 2d 540 (United States Ex Rel. Bogart v. King Pharmaceuticals) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States Ex Rel. Summers v. LHC Group, Inc.
623 F.3d 287 (Sixth Circuit, 2010)